Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. / Leucci, E; Zriwil, A; Gregersen, L H; Jensen, K T; Obad, S; Bellan, C; Leoncini, L; Kauppinen, S; Lund, A H.

In: Oncogene, Vol. 31, 2012, p. 5081–5089 .

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Leucci, E, Zriwil, A, Gregersen, LH, Jensen, KT, Obad, S, Bellan, C, Leoncini, L, Kauppinen, S & Lund, AH 2012, 'Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo', Oncogene, vol. 31, pp. 5081–5089 . https://doi.org/10.1038/onc.2012.15

APA

Leucci, E., Zriwil, A., Gregersen, L. H., Jensen, K. T., Obad, S., Bellan, C., Leoncini, L., Kauppinen, S., & Lund, A. H. (2012). Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. Oncogene, 31, 5081–5089 . https://doi.org/10.1038/onc.2012.15

Vancouver

Leucci E, Zriwil A, Gregersen LH, Jensen KT, Obad S, Bellan C et al. Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. Oncogene. 2012;31:5081–5089 . https://doi.org/10.1038/onc.2012.15

Author

Leucci, E ; Zriwil, A ; Gregersen, L H ; Jensen, K T ; Obad, S ; Bellan, C ; Leoncini, L ; Kauppinen, S ; Lund, A H. / Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. In: Oncogene. 2012 ; Vol. 31. pp. 5081–5089 .

Bibtex

@article{f78ca1ce0c9d4cf09860f2af2ad68d8f,
title = "Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo",
abstract = "MicroRNAs are important regulators of gene expression in normal development and disease. miR-9 is overexpressed in several cancer forms, including brain tumours, hepatocellular carcinomas, breast cancer and Hodgkin lymphoma (HL). Here we demonstrated a relevance for miR-9 in HL pathogenesis and identified two new targets Dicer1 and HuR. HL is characterized by a massive infiltration of immune cells and fibroblasts in the tumour, whereas malignant cells represent only 1% of the tumour mass. These infiltrates provide important survival and growth signals to the tumour cells, and several lines of evidence indicate that they are essential for the persistence of HL. We show that inhibition of miR-9 leads to derepression of DICER and HuR, which in turn results in a decrease in cytokine production by HL cells followed by an impaired ability to attract normal inflammatory cells. Finally, inhibition of miR-9 by a systemically delivered antimiR-9 in a xenograft model of HL increases the protein levels of HuR and DICER1 and results in decreased tumour outgrowth, confirming that miR-9 actively participates in HL pathogenesis and points to miR-9 as a potential therapeutic target.Oncogene advance online publication, 6 February 2012; doi:10.1038/onc.2012.15.",
author = "E Leucci and A Zriwil and Gregersen, {L H} and Jensen, {K T} and S Obad and C Bellan and L Leoncini and S Kauppinen and Lund, {A H}",
year = "2012",
doi = "10.1038/onc.2012.15",
language = "English",
volume = "31",
pages = "5081–5089 ",
journal = "Oncogene",
issn = "0950-9232",
publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo

AU - Leucci, E

AU - Zriwil, A

AU - Gregersen, L H

AU - Jensen, K T

AU - Obad, S

AU - Bellan, C

AU - Leoncini, L

AU - Kauppinen, S

AU - Lund, A H

PY - 2012

Y1 - 2012

N2 - MicroRNAs are important regulators of gene expression in normal development and disease. miR-9 is overexpressed in several cancer forms, including brain tumours, hepatocellular carcinomas, breast cancer and Hodgkin lymphoma (HL). Here we demonstrated a relevance for miR-9 in HL pathogenesis and identified two new targets Dicer1 and HuR. HL is characterized by a massive infiltration of immune cells and fibroblasts in the tumour, whereas malignant cells represent only 1% of the tumour mass. These infiltrates provide important survival and growth signals to the tumour cells, and several lines of evidence indicate that they are essential for the persistence of HL. We show that inhibition of miR-9 leads to derepression of DICER and HuR, which in turn results in a decrease in cytokine production by HL cells followed by an impaired ability to attract normal inflammatory cells. Finally, inhibition of miR-9 by a systemically delivered antimiR-9 in a xenograft model of HL increases the protein levels of HuR and DICER1 and results in decreased tumour outgrowth, confirming that miR-9 actively participates in HL pathogenesis and points to miR-9 as a potential therapeutic target.Oncogene advance online publication, 6 February 2012; doi:10.1038/onc.2012.15.

AB - MicroRNAs are important regulators of gene expression in normal development and disease. miR-9 is overexpressed in several cancer forms, including brain tumours, hepatocellular carcinomas, breast cancer and Hodgkin lymphoma (HL). Here we demonstrated a relevance for miR-9 in HL pathogenesis and identified two new targets Dicer1 and HuR. HL is characterized by a massive infiltration of immune cells and fibroblasts in the tumour, whereas malignant cells represent only 1% of the tumour mass. These infiltrates provide important survival and growth signals to the tumour cells, and several lines of evidence indicate that they are essential for the persistence of HL. We show that inhibition of miR-9 leads to derepression of DICER and HuR, which in turn results in a decrease in cytokine production by HL cells followed by an impaired ability to attract normal inflammatory cells. Finally, inhibition of miR-9 by a systemically delivered antimiR-9 in a xenograft model of HL increases the protein levels of HuR and DICER1 and results in decreased tumour outgrowth, confirming that miR-9 actively participates in HL pathogenesis and points to miR-9 as a potential therapeutic target.Oncogene advance online publication, 6 February 2012; doi:10.1038/onc.2012.15.

U2 - 10.1038/onc.2012.15

DO - 10.1038/onc.2012.15

M3 - Journal article

C2 - 22310293

VL - 31

SP - 5081

EP - 5089

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -

ID: 37594544